Analysts Set Karyopharm Therapeutics Inc. (NASDAQ:KPTI) PT at $43.20

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has been given an average recommendation of “Buy” by the five research firms that are presently covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have covered the stock in the last year is $43.20.

Several brokerages have issued reports on KPTI. Robert W. Baird cut their target price on Karyopharm Therapeutics from $54.00 to $42.00 and set an “outperform” rating for the company in a research note on Tuesday, May 13th. Wall Street Zen lowered Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 14th. Royal Bank Of Canada cut their target price on Karyopharm Therapeutics from $34.00 to $33.00 and set an “outperform” rating for the company in a research note on Tuesday, May 13th. Finally, Barclays upped their target price on Karyopharm Therapeutics from $5.00 to $10.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 13th.

Karyopharm Therapeutics Trading Up 0.2%

Shares of NASDAQ KPTI opened at $4.62 on Wednesday. Karyopharm Therapeutics has a 12 month low of $3.51 and a 12 month high of $16.95. The firm has a market capitalization of $39.92 million, a price-to-earnings ratio of -0.35 and a beta of 0.24. The business has a 50-day moving average of $4.97 and a 200-day moving average of $6.85.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Monday, May 12th. The company reported ($2.77) EPS for the quarter, topping the consensus estimate of ($4.21) by $1.44. The business had revenue of $30.02 million for the quarter, compared to analysts’ expectations of $35.12 million. On average, analysts predict that Karyopharm Therapeutics will post -0.71 earnings per share for the current year.

Institutional Trading of Karyopharm Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. T. Rowe Price Investment Management Inc. purchased a new stake in shares of Karyopharm Therapeutics during the first quarter valued at approximately $523,000. Velan Capital Investment Management LP purchased a new stake in shares of Karyopharm Therapeutics during the fourth quarter valued at approximately $27,000. Two Sigma Advisers LP boosted its stake in shares of Karyopharm Therapeutics by 145.5% during the fourth quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock valued at $52,000 after purchasing an additional 45,400 shares during the period. Two Sigma Investments LP boosted its stake in shares of Karyopharm Therapeutics by 60.3% during the fourth quarter. Two Sigma Investments LP now owns 137,786 shares of the company’s stock valued at $93,000 after purchasing an additional 51,856 shares during the period. Finally, Shay Capital LLC purchased a new stake in shares of Karyopharm Therapeutics during the fourth quarter valued at approximately $116,000. Hedge funds and other institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).